by Elena Iemma | Jan 12, 2026 | Blog, News
In 2025, EpiVax advanced the science of immunogenicity assessment through AI-driven ADA prediction, enhanced in silico tools, expanded in vitro assays and consulting offerings, and new regulatory frameworks supporting biologics and generic peptides. Advancing...
by Elena Iemma | Apr 30, 2025 | Blog
Is “Artificial” Intelligence an Option for your ADA? In Case You Missed It: Better ADA Prediction! Guilhem Richard, our CTO, recently presented our new ADA (anti-drug antibody) prediction model to the Antibody Society. The accuracy of the model improved...
by Elena Iemma | Feb 27, 2025 | News
EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements PROVIDENCE, R.I., Feb. 27, 2025 — EpiVax, Inc. proudly announces the appointment of Guilhem Richard as Chief Technology Officer. Dr. Richard joined EpiVax’s immunoinformatics team in 2014 and...
by Elena Iemma | Apr 4, 2023 | Events
Thank you to everyone who participated in the 9th annual Amsterdam Immunogenicity and Tolerance Seminar! The day would not have been such a success without you. Check out these photos from the event. A special thanks to the Seminar organizing committee: Corine...
by Elena Iemma | Mar 3, 2023 | Events
The EpiVax team had a great time in Tokyo hosting the 15th annual Westin Immunogenicity Seminar! Thank you to all who were in attendance. See pictures from the event below. Interested in attending the Westin Immunogenicity Seminar in 2024? Sign up here! The 15th...
